JP2007514769A - 1−アルカン−2−オール置換ピペラジンおよびピペリジン化合物 - Google Patents

1−アルカン−2−オール置換ピペラジンおよびピペリジン化合物 Download PDF

Info

Publication number
JP2007514769A
JP2007514769A JP2006545566A JP2006545566A JP2007514769A JP 2007514769 A JP2007514769 A JP 2007514769A JP 2006545566 A JP2006545566 A JP 2006545566A JP 2006545566 A JP2006545566 A JP 2006545566A JP 2007514769 A JP2007514769 A JP 2007514769A
Authority
JP
Japan
Prior art keywords
yloxy
methylbenzothiazol
piperazinyl
propyl
hydroxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2006545566A
Other languages
English (en)
Japanese (ja)
Other versions
JP2007514769A5 (cg-RX-API-DMAC7.html
Inventor
エルファティー・エルザイン
プラバ・イブラヒム
ヴェンカタ・パレ
ケネス・レーダー
ジェフリー・エイ・ザブロッキ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Gilead Palo Alto Inc
Original Assignee
CV Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by CV Therapeutics Inc filed Critical CV Therapeutics Inc
Publication of JP2007514769A publication Critical patent/JP2007514769A/ja
Publication of JP2007514769A5 publication Critical patent/JP2007514769A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/56—Nitrogen atoms
    • C07D211/58—Nitrogen atoms attached in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • C07D277/64—Benzothiazoles with only hydrocarbon or substituted hydrocarbon radicals attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP2006545566A 2003-12-18 2004-12-17 1−アルカン−2−オール置換ピペラジンおよびピペリジン化合物 Pending JP2007514769A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US53125303P 2003-12-18 2003-12-18
PCT/US2004/042859 WO2005061470A1 (en) 2003-12-18 2004-12-17 1-akan-2-ol substituted piperazine and piperidine compounds

Publications (2)

Publication Number Publication Date
JP2007514769A true JP2007514769A (ja) 2007-06-07
JP2007514769A5 JP2007514769A5 (cg-RX-API-DMAC7.html) 2008-01-24

Family

ID=34710215

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006545566A Pending JP2007514769A (ja) 2003-12-18 2004-12-17 1−アルカン−2−オール置換ピペラジンおよびピペリジン化合物

Country Status (7)

Country Link
US (4) US7115610B2 (cg-RX-API-DMAC7.html)
EP (1) EP1723129A1 (cg-RX-API-DMAC7.html)
JP (1) JP2007514769A (cg-RX-API-DMAC7.html)
KR (1) KR20060124646A (cg-RX-API-DMAC7.html)
AU (1) AU2004303882A1 (cg-RX-API-DMAC7.html)
CA (1) CA2550257A1 (cg-RX-API-DMAC7.html)
WO (1) WO2005061470A1 (cg-RX-API-DMAC7.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024515895A (ja) * 2021-05-07 2024-04-10 メルク・シャープ・アンド・ドーム・エルエルシー Nav1.8阻害薬としてのシクロアルキル 3-オキソピペラジンカルボキサミド類及びシクロヘテロアルキル 3-オキソピペラジンカルボキサミド類

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2550257A1 (en) * 2003-12-18 2005-07-07 Cv Therapeutics, Inc. 1-akan-2-ol substituted piperazine and piperidine compounds
EP1829866A1 (en) * 2006-03-02 2007-09-05 Laboratorios Del Dr. Esteve, S.A. Sigma receptor inhibitors
BRPI0913291A2 (pt) 2008-05-30 2019-01-15 Takeda Pharmaceuticals Co composto, pró-droga, medicamento, métodos para diminuir a proteína 4 ou tratamento de diabete em um mamífero, e, uso do composto
CN105175401A (zh) * 2015-10-16 2015-12-23 北京康立生医药技术开发有限公司 一种依匹哌唑的制备方法

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH04264078A (ja) * 1990-10-31 1992-09-18 Richter Gedeon V G Rt ピペラジン誘導体の製造方法
WO2001060348A2 (en) * 2000-02-18 2001-08-23 Cv Therapeutics, Inc. Partial fatty acid oxidation inhibitors in the treatment of congestive heart failure
WO2002064576A1 (en) * 2000-10-23 2002-08-22 Cv Therapeutics, Inc. Heteroaryl alkyl piperazine derivatives as fatty acid oxidation inhibitors
WO2003008411A1 (en) * 2001-07-19 2003-01-30 Cv Therapeutics, Inc. Substituted piperazine compounds and their use as fatty acid oxidation inhibitors
WO2003049680A2 (en) * 2001-12-05 2003-06-19 Peirce Management, Llc Compositions containing both sedative and non-sedative antihistamines
WO2003075091A1 (en) * 2002-03-05 2003-09-12 Ciba Specialty Chemicals Holding Inc. Colour photographic recording material
JP2003531116A (ja) * 2000-02-22 2003-10-21 スィーヴィー セラピューティクス インコーポレイテッド 置換ピペラジン化合物
WO2003086401A1 (en) * 2002-04-04 2003-10-23 Cv Therapeutics, Inc. Use of ranolazine for the preparation of a medicament for the treatment of arrhythmias

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2034305B (en) * 1978-10-24 1982-12-22 Wyeth John & Brother Ltd Preparation of piperidine derivatives
DE3118881A1 (de) 1980-09-29 1982-06-24 Oltmanns Ziegel Und Kunststoffe Gmbh, 2905 Edewecht "ziegel"
US4766125A (en) 1981-06-23 1988-08-23 Janssen Pharmaceutica N.V. N-aryl-piperazinealkanamides useful for protecting hearts from myocardial injury caused by ischaemia, anoxia or hypoxia
US4558129A (en) 1983-05-18 1985-12-10 Syntex (U.S.A.) Inc. Benzodioxanyl-hydroxyethylene-piperazinyl acetanilides which effect calcium entry and β-blockade
US4567264A (en) 1983-05-18 1986-01-28 Syntex (U.S.A.) Inc. Cardioselective aryloxy- and arylthio- hydroxypropylene-piperazinyl acetanilides which affect calcium entry
ES2177601T3 (es) 1989-06-23 2002-12-16 Syntex Llc Ranolazina y pepeerazinas relacionadas para uso en el tratamiento de estados de choque. .
US5455045A (en) 1993-05-13 1995-10-03 Syntex (U.S.A.) Inc. High dose formulations
AU2001238590A1 (en) 2000-02-22 2001-09-03 Cv Therapeutics, Inc. Substituted piperazine compounds
US6451798B2 (en) 2000-02-22 2002-09-17 Cv Therapeutics, Inc. Substituted alkyl piperazine derivatives
US6677336B2 (en) 2000-02-22 2004-01-13 Cv Therapeutics, Inc. Substituted piperazine compounds
US6552023B2 (en) 2000-02-22 2003-04-22 Cv Therapeutics, Inc. Aralkyl substituted piperazine compounds
IL151626A0 (en) * 2000-04-07 2003-04-10 Astrazeneca Ab Quinazoline compounds
US7001909B2 (en) 2001-07-19 2006-02-21 Cv Therapeutics, Inc. Substituted heterocyclic compounds
CA2550257A1 (en) * 2003-12-18 2005-07-07 Cv Therapeutics, Inc. 1-akan-2-ol substituted piperazine and piperidine compounds

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH04264078A (ja) * 1990-10-31 1992-09-18 Richter Gedeon V G Rt ピペラジン誘導体の製造方法
WO2001060348A2 (en) * 2000-02-18 2001-08-23 Cv Therapeutics, Inc. Partial fatty acid oxidation inhibitors in the treatment of congestive heart failure
JP2003531116A (ja) * 2000-02-22 2003-10-21 スィーヴィー セラピューティクス インコーポレイテッド 置換ピペラジン化合物
WO2002064576A1 (en) * 2000-10-23 2002-08-22 Cv Therapeutics, Inc. Heteroaryl alkyl piperazine derivatives as fatty acid oxidation inhibitors
WO2003008411A1 (en) * 2001-07-19 2003-01-30 Cv Therapeutics, Inc. Substituted piperazine compounds and their use as fatty acid oxidation inhibitors
WO2003049680A2 (en) * 2001-12-05 2003-06-19 Peirce Management, Llc Compositions containing both sedative and non-sedative antihistamines
WO2003075091A1 (en) * 2002-03-05 2003-09-12 Ciba Specialty Chemicals Holding Inc. Colour photographic recording material
WO2003086401A1 (en) * 2002-04-04 2003-10-23 Cv Therapeutics, Inc. Use of ranolazine for the preparation of a medicament for the treatment of arrhythmias

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024515895A (ja) * 2021-05-07 2024-04-10 メルク・シャープ・アンド・ドーム・エルエルシー Nav1.8阻害薬としてのシクロアルキル 3-オキソピペラジンカルボキサミド類及びシクロヘテロアルキル 3-オキソピペラジンカルボキサミド類
JP7522943B2 (ja) 2021-05-07 2024-07-25 メルク・シャープ・アンド・ドーム・エルエルシー Nav1.8阻害薬としてのシクロアルキル 3-オキソピペラジンカルボキサミド類及びシクロヘテロアルキル 3-オキソピペラジンカルボキサミド類

Also Published As

Publication number Publication date
WO2005061470A1 (en) 2005-07-07
US20060229317A1 (en) 2006-10-12
AU2004303882A1 (en) 2005-07-07
US7115610B2 (en) 2006-10-03
EP1723129A1 (en) 2006-11-22
US7452889B2 (en) 2008-11-18
US20080032993A1 (en) 2008-02-07
KR20060124646A (ko) 2006-12-05
US7262198B2 (en) 2007-08-28
US20050197346A1 (en) 2005-09-08
CA2550257A1 (en) 2005-07-07
US20090054457A1 (en) 2009-02-26

Similar Documents

Publication Publication Date Title
DE60203623T2 (de) Substituierte piperazinderivate und ihre verwendung als fettsaüre-oxidationsinhibitoren
US7452889B2 (en) Substituted heterocyclic compounds
US7407960B2 (en) Substituted heterocyclic compounds
US7026321B2 (en) Substituted heterocyclic compounds
US7271169B2 (en) Substituted heterocyclic compounds
EP1806346B1 (en) Substituted piperazine compounds and their use as fatty acid oxidation inhibitors
JP2006516036A (ja) 置換ヘテロ環式化合物
US20070191390A1 (en) Substituted heterocyclic compounds
HK1083492B (en) Substituted piperazine compounds and their use as fatty acid oxidation inhibitors
HK1111683B (en) Substituted piperazine compounds and their use as fatty acid oxidation inhibitors

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20071129

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20071129

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20110830